Literature DB >> 20034048

Protective effect of human leukocyte antigen B27 in hepatitis C virus infection requires the presence of a genotype-specific immunodominant CD8+ T-cell epitope.

Christoph Neumann-Haefelin1,2,3, Jörg Timm4, Julia Schmidt1,2,5, Nadine Kersting1, Karen Fitzmaurice6, Cesar Oniangue-Ndza3, Michael N Kemper3, Isla Humphreys7, Susan McKiernan6, Dermot Kelleher6, Volker Lohmann8, Paul Bowness9, Daniela Huzly10, Hugo R Rosen11, Arthur Y Kim3, Georg M Lauer3, Todd M Allen3, Eleanor Barnes7, Michael Roggendorf4, Hubert E Blum1, Robert Thimme1.   

Abstract

UNLABELLED: Human leukocyte antigen B27 (HLA-B27) is associated with protection in human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection. This protective role is linked to single immunodominant HLA-B27-restricted CD8+ T-cell epitopes in both infections. In order to define the relative contribution of a specific HLA-B27-restricted epitope to the natural course of HCV infection, we compared the biological impact of the highly conserved HCV genotype 1 epitope, for which the protective role has been described, with the corresponding region in genotype 3 that differs in its sequence by three amino acid residues. The genotype 3a peptide was not recognized by CD8+ T cells specific for the genotype 1 peptide. Furthermore, patients with acute or chronic infection with HCV genotype 3a did not mount T-cell responses to this epitope region, and their autologous viral sequences showed no evidence of T-cell pressure. Finally, we found a significantly higher frequency of HLA-B27 positivity in patients with chronic HCV genotype 3a infection compared to genotype 1 infection, indicating that there is no protection by HLA-B27 in HCV genotype 3 infection.
CONCLUSION: Our data indicate that the protective effect of HLA-B27 is limited to HCV genotype 1 infection and does not expand to other genotypes such as genotype 3a. This can most likely be explained by intergenotype sequence diversity leading to the loss of the immunodominant HLA-B27 epitope in viral strains other than genotype 1. Our results underline the central role of a single HLA-B27-restricted epitope-specific CD8+ T-cell response in mediating protection in HCV genotype 1 infection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20034048      PMCID: PMC4396188          DOI: 10.1002/hep.23275

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  28 in total

1.  New allele frequency database: http://www.allelefrequencies.net.

Authors:  D Middleton; L Menchaca; H Rood; R Komerofsky
Journal:  Tissue Antigens       Date:  2003-05

2.  Crystal structures and KIR3DL1 recognition of three immunodominant viral peptides complexed to HLA-B*2705.

Authors:  Guillame B E Stewart-Jones; Kati di Gleria; Simon Kollnberger; Andrew J McMichael; E Yvonne Jones; Paul Bowness
Journal:  Eur J Immunol       Date:  2005-02       Impact factor: 5.532

3.  Evolution and transmission of stable CTL escape mutations in HIV infection.

Authors:  P J Goulder; C Brander; Y Tang; C Tremblay; R A Colbert; M M Addo; E S Rosenberg; T Nguyen; R Allen; A Trocha; M Altfeld; S He; M Bunce; R Funkhouser; S I Pelton; S K Burchett; K McIntosh; B T Korber; B D Walker
Journal:  Nature       Date:  2001-07-19       Impact factor: 49.962

4.  Degree of cross-genotype reactivity of hepatitis C virus-specific CD8+ T cells directed against NS3.

Authors:  Silvia Giugliano; Filiz Oezkan; Mathias Bedrejowski; Markus Kudla; Markus Reiser; Sergei Viazov; Norbert Scherbaum; Michael Roggendorf; Joerg Timm
Journal:  Hepatology       Date:  2009-09       Impact factor: 17.425

5.  Host ethnicity and virus genotype shape the hepatitis B virus-specific T-cell repertoire.

Authors:  Anthony Tanoto Tan; Elisabetta Loggi; Carolina Boni; Adeline Chia; Adam J Gehring; Konduru S R Sastry; Vera Goh; Paola Fisicaro; Pietro Andreone; Christian Brander; Seng Gee Lim; Carlo Ferrari; Florian Bihl; Antonio Bertoletti
Journal:  J Virol       Date:  2008-09-17       Impact factor: 5.103

Review 6.  Peptides: the cornerstone of HLA-B27 biology and pathogenetic role in spondyloarthritis.

Authors:  M Marcilla; J A López de Castro
Journal:  Tissue Antigens       Date:  2008-06

7.  HLA footprints on human immunodeficiency virus type 1 are associated with interclade polymorphisms and intraclade phylogenetic clustering.

Authors:  Philippa C Matthews; Alasdair J Leslie; Aris Katzourakis; Hayley Crawford; Rebecca Payne; Andrew Prendergast; Karen Power; Anthony D Kelleher; Paul Klenerman; Jonathan Carlson; David Heckerman; Thumbi Ndung'u; Bruce D Walker; Todd M Allen; Oliver G Pybus; Philip J R Goulder
Journal:  J Virol       Date:  2009-02-25       Impact factor: 5.103

8.  NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11.

Authors:  Claus Lundegaard; Kasper Lamberth; Mikkel Harndahl; Søren Buus; Ole Lund; Morten Nielsen
Journal:  Nucleic Acids Res       Date:  2008-05-07       Impact factor: 16.971

9.  Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response.

Authors:  Eva Dazert; Christoph Neumann-Haefelin; Stéphane Bressanelli; Karen Fitzmaurice; Julia Kort; Jörg Timm; Susan McKiernan; Dermot Kelleher; Norbert Gruener; John E Tavis; Hugo R Rosen; Jaqueline Shaw; Paul Bowness; Hubert E Blum; Paul Klenerman; Ralf Bartenschlager; Robert Thimme
Journal:  J Clin Invest       Date:  2009-01-12       Impact factor: 14.808

10.  Protective effect of HLA-B57 on HCV genotype 2 infection in a West African population.

Authors:  Wing Chia-Ming Chuang; Francis Sarkodie; Colin J Brown; Shirley Owusu-Ofori; Juliette Brown; Chengyao Li; Cristina Navarrete; Paul Klenerman; Jean-Pierre Allain
Journal:  J Med Virol       Date:  2007-06       Impact factor: 2.327

View more
  29 in total

1.  Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia.

Authors:  Mark H Kuniholm; Andrea Kovacs; Xiaojiang Gao; Xiaonan Xue; Darlene Marti; Chloe L Thio; Marion G Peters; Norah A Terrault; Ruth M Greenblatt; James J Goedert; Mardge H Cohen; Howard Minkoff; Stephen J Gange; Kathryn Anastos; Melissa Fazzari; Tiffany G Harris; Mary A Young; Howard D Strickler; Mary Carrington
Journal:  Hepatology       Date:  2010-05       Impact factor: 17.425

2.  Human leukocyte antigen B27 selects for rare escape mutations that significantly impair hepatitis C virus replication and require compensatory mutations.

Authors:  Christoph Neumann-Haefelin; Cesar Oniangue-Ndza; Thomas Kuntzen; Julia Schmidt; Katja Nitschke; John Sidney; Célia Caillet-Saguy; Marco Binder; Nadine Kersting; Michael W Kemper; Karen A Power; Susan Ingber; Laura L Reyor; Kelsey Hills-Evans; Arthur Y Kim; Georg M Lauer; Volker Lohmann; Alessandro Sette; Matthew R Henn; Stéphane Bressanelli; Robert Thimme; Todd M Allen
Journal:  Hepatology       Date:  2011-10       Impact factor: 17.425

Review 3.  Update on hepatitis C virus-specific immunity.

Authors:  Donatella Ciuffreda; Arthur Y Kim
Journal:  Curr Opin HIV AIDS       Date:  2011-11       Impact factor: 4.283

4.  Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes.

Authors:  Arthur Y Kim; Thomas Kuntzen; Joerg Timm; Brian E Nolan; Melanie A Baca; Laura L Reyor; Andrew C Berical; Andrea J Feller; Kristin L Johnson; Julian Schulze zur Wiesch; Gregory K Robbins; Raymond T Chung; Bruce D Walker; Mary Carrington; Todd M Allen; Georg M Lauer
Journal:  Gastroenterology       Date:  2010-09-24       Impact factor: 22.682

5.  Spontaneous clearance of hepatitis C virus in vertically infected children.

Authors:  Susan Farmand; Stefan Wirth; Helga Löffler; Tanja Woltering; Sybille Kenzel; Elke Lainka; Philipp Henneke
Journal:  Eur J Pediatr       Date:  2011-07-07       Impact factor: 3.183

Review 6.  Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection.

Authors:  Barbara Rehermann; Robert Thimme
Journal:  Gastroenterology       Date:  2018-09-26       Impact factor: 22.682

Review 7.  Current progress in development of hepatitis C virus vaccines.

Authors:  T Jake Liang
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

8.  Amino Acid Substitutions within HLA-B*27-Restricted T Cell Epitopes Prevent Recognition by Hepatitis Delta Virus-Specific CD8+ T Cells.

Authors:  Hadi Karimzadeh; Muthamia M Kiraithe; Anna D Kosinska; Manuel Glaser; Melanie Fiedler; Valerie Oberhardt; Elahe Salimi Alizei; Maike Hofmann; Juk Yee Mok; Melanie Nguyen; Wim J E van Esch; Bettina Budeus; Jan Grabowski; Maria Homs; Antonella Olivero; Hossein Keyvani; Francisco Rodríguez-Frías; David Tabernero; Maria Buti; Andreas Heinold; Seyed Moayed Alavian; Tanja Bauer; Julian Schulze Zur Wiesch; Bijan Raziorrouh; Daniel Hoffmann; Antonina Smedile; Mario Rizzetto; Heiner Wedemeyer; Jörg Timm; Iris Antes; Christoph Neumann-Haefelin; Ulrike Protzer; Michael Roggendorf
Journal:  J Virol       Date:  2018-06-13       Impact factor: 5.103

9.  Synergism of tapasin and human leukocyte antigens in resolving hepatitis C virus infection.

Authors:  Shirin Ashraf; Katja Nitschke; Usama M Warshow; Collin R Brooks; Arthur Y Kim; Georg M Lauer; Theresa J Hydes; Matthew E Cramp; Graeme Alexander; Ann-Margaret Little; Robert Thimme; Christoph Neumann-Haefelin; Salim I Khakoo
Journal:  Hepatology       Date:  2013-07-29       Impact factor: 17.425

10.  Impact of sequence variation in a dominant HLA-A*02-restricted epitope in hepatitis C virus on priming and cross-reactivity of CD8+ T cells.

Authors:  Susanne Ziegler; Kathrin Skibbe; Andreas Walker; Xiaoyu Ke; Falko M Heinemann; Andreas Heinold; Juk Yee Mok; Wim J E van Esch; Dongliang Yang; Matthias Wölfl; Jörg Timm
Journal:  J Virol       Date:  2014-07-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.